{"abstract":"The National Heart, Lung and Blood Institute (NHLBI), National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive commercialization patent license to Sinotau Pharmaceutical Group, headquartered in Beijing, China, to practice the inventions embodied in the patent application(s) listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2018/07/27/2018-16066.html","cfr_references":[],"citation":"83 FR 35667","comment_url":null,"comments_close_on":"2018-08-27","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the NHLBI Office of Technology Transfer and Development August 27, 2018 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2018-16066","effective_on":null,"end_page":35667,"executive_order_notes":null,"executive_order_number":null,"explanation":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2018/07/27/2018-16066.xml","html_url":"https://www.federalregister.gov/documents/2018/07/27/2018-16066/prospective-grant-of-exclusive-patent-license-radiotherapy-for-metastatic-castration-resistant","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2018-16066?publication_date=2018-07-27","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2018-07-27/2018-16066/mods.xml","not_received_for_publication":null,"page_length":1,"page_views":{"count":492,"last_updated":"2026-04-04 14:15:05 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2018-07-27/pdf/2018-16066.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2018-16066.pdf?1532609125","publication_date":"2018-07-27","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2018/07/27/2018-16066.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-03-01T06:36:32Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":35667,"subtype":null,"title":"Prospective Grant of Exclusive Patent License: Radiotherapy for Metastatic Castration-Resistant Prostate Cancer","toc_doc":"Radiotherapy for Metastatic Castration-resistant Prostate Cancer","toc_subject":"Prospective Grants of Exclusive Patent Licenses:","topics":[],"type":"Notice","volume":83}